Patheon Completes Plan of Arrangement

 TORONTO, March 11, 2014 /CNW/ - Patheon Inc. (TSX: PTI) ("Patheon") announced  today the completion of the previously announced statutory plan of arrangement  (the "Arrangement") under section 192 of the Canada Business Corporations Act,  pursuant to the arrangement agreement between Patheon and JLL/Delta Patheon  Holdings, L.P. ("DPx") dated November 18, 2013. DPx is sponsored by an entity  controlled by an affiliate of JLL Partners, Inc. ("JLL") and Koninklijke DSM  N.V. ("DSM").  Pursuant to the Arrangement, DPx indirectly acquired all of the issued and  outstanding restricted voting shares of Patheon at a price of US$9.32 cash for  each share. All of the outstanding options of Patheon were deemed to be vested  and holders are entitled to receive a cash amount equal to the amount by which  US$9.32 exceeds the exercise price of such option. All options with an  exercise price equal to or greater than US$9.32 were cancelled without  consideration. All payments are subject to applicable withtholding taxes, if  any.  For registered holders of Patheon's restricted voting shares, payment of the  consideration will be processed after holders deposit their share certificates  with Computershare Trust Company of Canada (the "Depositary"), in accordance  with the instructions in the Letter of Transmittal previously sent to  registered shareholders. Any questions regarding payment of the consideration,  including any request for another form of Letter of Transmittal, should be  directed to the Depositary via telephone at 1 (800) 564-6253 (toll free in  North America) or via email at  Non-registered shareholders will receive payment of the consideration through  their broker, investment dealer, bank, trust company or other intermediary  that holds the restricted voting shares on their behalf. Non-registered  shareholders should contact their broker or other intermediary for further  details.  Patheon has withdrawn its shares from registration with the United States  Securities and Exchange Commission. Delisting of the restricted voting shares  from the Toronto Stock Exchange is expected to occur shortly. As soon as  practicable after the delisting of its restricted voting shares, Patheon will  apply to all applicable Canadian securities regulatory authorities to cease to  be a reporting issuer.  Pursuant to the Arrangement, Patheon was amalgamated with JLL/Delta Canada  Inc., an indirect subsidiary of DPx, and will continue to carry on business  under the name "Patheon Inc."  In connection with the completion of the Arrangement, DSM's DSM Pharmaceutical  Products ("DPP") business group was combined with Patheon.  Further details with respect to the Arrangement can be found in Patheon's  proxy statement and management information circular dated February 4, 2014.  About Patheon Inc.  Patheon Inc. is a leading provider of contract development and commercial  manufacturing services to the global pharmaceutical industry for a full array  of solid and sterile dosage forms. Through the company's recent acquisition of  Banner Pharmacaps - a market leader in soft gelatin capsule technology  -Patheon now also includes a proprietary products and technology business.  Patheon provides the highest quality products and services to approximately  300 of the world's leading pharmaceutical and biotechnology companies. The  company's integrated network consists of 15 locations, including 12 commercial  contract manufacturing facilities and 9 development centers across North  America and Europe. Patheon enables customer products to be launched with  confidence anywhere in the world. For more information visit  This press release is issued in compliance with section 102.1 of the  Securities Act (Ontario) and National Instrument 62-103 The Early Warning  System and Related Take-Over Bid and Insider Reporting Issues in connection  with the acquisition by JLL/Delta Canada Inc., an indirect wholly owned  subsidiary of DPx, of all of the restricted voting shares of Patheon pursuant  to the Arrangement. A press release and early warning report in respect of the  acquisition of all of the restricted voting shares of Patheon pursuant to the  Arrangement will be filed with the applicable securities commission or  securities regulator in each jurisdiction in which the Patheon is a reporting  issuer.  JLL/Delta Canada Inc. 2100 Syntex Court Mississauga, Ontario, Canada L5N 7K9  To obtain a copy of the early warning report, please contact Daniel Agroskin  at 212-286-8600.  Cautionary Statement  No stock exchange, securities commission or other regulatory authority has  approved or disapproved the information contained herein.    SOURCE  Patheon Inc.  Contact: Patheon Inc. Tel: (919) 226-3200  To view this news release in HTML formatting, please use the following URL:  CO: Patheon Inc. ST: Ontario NI: MTC FIN MNA